Abstracts tagged "infection and rheumatoid arthritis (RA)"

Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 2761 • 2013 ACR/ARHP Annual Meeting
Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several newer biologics have been approved for treatment of rheumatoid arthritis (RA) in the United States. However, their comparative risks of herpes zoster infection…
Abstract Number: 2680 • 2013 ACR/ARHP Annual Meeting
Risk of Subsequent Infection among Rheumatoid Arthritis Patients Using Biologics
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Much has been written about infections associated with biologic agents in patients with rheumatoid arthritis (RA). However, less is known about the risk of…
Abstract Number: 1140 • 2013 ACR/ARHP Annual Meeting
Study Of The Antibody Titer By Influenza Vaccination In Rheumatoid Arthritis Patients Treated With Biologics In JAPAN
Hisato Ishikawa¹, Daihei Kida², Yosuke Hattori³, Atsushi Kaneko³ and Tomotaro Sato⁴, ¹Nagoya Medical Center, nagano, Japan, ²Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopaedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan
Background/Purpose: Vaccination for influenza virus is recommended for patients with rheumatoid arthritis (RA) with underlying such as disease elderly people over the age of 65,…
Abstract Number: 1047 • 2013 ACR/ARHP Annual Meeting
Rates Of Hospitalized Infections In Rheumatoid Arthritis Patients From 5 Rheumatoid Arthritis Registries Across The World
Hisashi Yamanaka¹, Johan Askling², Niklas Berglind³, Stefan Franzén³, Thomas Frisell⁴, Christopher Garwood⁵, Jeffrey D. Greenberg⁶, Meilien Ho⁷, Marie Holmqvist², Laura Horne⁸, Eisuke Inoue¹, Kathy Lampl⁹, Kaleb Michaud¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Deborah Symmons⁵, Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁵ and Fredrik Nyberg¹⁵, ¹Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Karolinska Institutet, Stockholm, Sweden, ³AstraZeneca R&D Mölndal, Mölndal, Sweden, ⁴Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶New York Hospital for Joint Disease, New York, NY, ⁷AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁸AstraZeneca, Wilmington, DE, ⁹AstraZeneca R&D Wilmington, Wilmington, DE, ¹⁰University of Nebraska Medical Center, Omaha, NE, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵AstraZeneca R&D, Mölndal, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of infection due to both RA itself and immunomodulating treatments. Infection rates are often difficult to…
Abstract Number: 486 • 2013 ACR/ARHP Annual Meeting
Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection
Jeffrey R. Curtis¹, Mary J. Burton², Shuo Yang³, Lang Chen⁴, Ted R. Mikuls⁵, Kevin L. Winthrop⁶ and John Baddley⁷, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²VA Hospital, Jackson, MS, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁶Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Among patients with rheumatoid arthritis and hepatitis B infection, the impact of biologic therapy on hepatotoxicity has received limited study. Methods: Using 1997-2011 national…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…
Abstract Number: 1309 • 2012 ACR/ARHP Annual Meeting
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Alain G. Cantagrel³, Bernard Combe⁴, René-Marc Flipo⁵, Thierry Schaeverbeke⁶, Eric Houvenagel⁷, Philippe Gaudin⁸, Damien Loeuille⁹, Stephanie Rist¹⁰, Maxime Dougados¹¹, Jean Sibilia¹², Xavier Le Loet¹³, Christian Marcelli¹⁴, Thomas Bardin¹⁵, Isabelle Pane¹⁶, Elodie Perrodeau¹⁷, Gabriel Baron¹⁸ and Xavier Mariette¹⁹, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Rheumatology Department, Lille University Hospital, Lille, France, ⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁷Service de Rhumatologie, St Philibert Hospital, Lomme 59462, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ¹⁰Hospital University Orléans, France, ¹¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹²Rheumatology, CHU Hautepierre, Strasbourg, France, ¹³Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁴Rheumatology Department, Caen University Hospital, ¹⁵Rheumatology, Hôpital Lariboisière, Paris, France, ¹⁶Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁷Epidemiologist, Paris, France, ¹⁸Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Little data is available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis treated with abatacept (ABA) in daily…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].